

Dott.ssa Monica N. Fornier

CURRICULUM VITAE

24/7/22
Monica Fornier

NOME:

MONICA N. FORNIER

NAZIONALITA':

Italiana e U.S.

STUDI COMPIUTI/TITOLI ACCADEMICI:

ISTITUZIONE	TITOLO	DATE
Memorial Sloan-Kettering Cancer Center, New York, NY, USA	Specializzazione in Oncologia	1998-2001
Universita' degli Studi di Milano, Scuola di Specializzazione in Oncologia	Specializzazione in Oncologia (70 e lode)	1994-1998
Borsa di Studio "INT-AIRC", Istituto Nazionale Tumori, Milano.		1993-1994
Borsa di Studio "Marco Semenza", Istituto Nazionale Tumori, Milano.		1992-1993
Universita' degli Studi di Milano, Facolta' di Medicina e Chirurgia	Laurea in Medicina e Chirurgia (110 e lode)	1992

INCARICHI PROFESSIONALI E ACCADEMICI:

Membro Associato (equivalente a Professore Associato) Breast Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY		2013- oggi
Professore Associato Weill Cornell Medical College, New York, NY		2013- oggi

Dott.ssa Monica N. Fornier

Professore a Contratto del corso di Oncologia Medica 4 Scuola di Specializzazione in Oncologia Medica Anni Accademici 2013-2014; 2014-2015 Matr. 49766 Universita' degli Studi di Milano	2014 - 2016
Membro Assistente, Breast Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY	2005-2013
Membro Assistente I, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY	2004- 2005
Assistant Professor Weill Cornell Medical College, New York, NY	2006-2013
Clinical Assistant Physician, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY	2001-2004
Instructor in Medicine Weill Cornell Medical College, New York, NY	2001-2006

AFFILIAZIONI A SOCIETA' SCIENTIFICHE:

ESMO (European Society of Clinical Oncology)
ASCO (American Society of Clinical Oncology)
ASBMR (American Society for Bone and Mineral Research)

LINGUE PARLATE:

Madrelingua italiana; inglese come seconda madrelingua; buona conoscenza del francese e del tedesco.

ATTIVITA' ASSISTENZIALE:

Attività assistenziale ambulatoriale, di Day Hospital e di reparto presso il Breast Medicine Service del Memorial Sloan-Kettering Cancer Center.

ATTIVITA' DIDATTICA:

Attività di insegnamento e mentorship a studenti e specializzandi in Medicina Interna ed in Oncologia presso il Memorial Sloan-Kettering Cancer Center ed il Weill Medical College.

Attività didattica per il "Memorial Sloan-Kettering Course for the Salzburg Medical Seminars International." Salzburg, Austria.

ATTIVITA' AMMINISTRATIVA:

2005-2007: Membro del comitato "Junior Faculty Council" per la mentorship degli specializzandi e dei nuovi membri della faculty.

2005- oggi: Membro del comitato "Pregnancy Committee" per la delineazione di un algoritmo per i tests di gravidanza prima di qualsiasi procedura medica.

Dott.ssa Monica N. Fornier

2008- oggi: Membro del comitato "NCCN Task Force Report: Bone Health in Cancer Care" per la delineazione di linee guida sull'uso dei farmaci anti-riassorbimento osseo, quali bifosfonati e denosumab.

2009- oggi: Membro dell'Adult Translational Research Advisory Committee, con attività di revisore di grants e progetti per il Clinical and Translational Science Center (CTSC), che comprende Weill Cornell Medical College and Graduate School, Cornell Ithaca, Cornell Cooperative Extension, NYC, Hunter College Gene Center and Nursing School, Hospital for Special Surgery e Memorial Sloan-Kettering Cancer Center.

2010 –oggi : Chair del New York Chapter di ISSNAF (Italian Scientists and Scholars of North America Foundation)

2021 -oggi: Membro del Research Council Committee del Memorial Sloan Kettering Cancer Center per la revisione dei protocolli di ricerca.

MEMBRO DELLE SEGUENTI ASSOCIAZIONI SCIENTIFICHE:

ASCO (American Society of Clinical Oncology)
ESMO (European Society of Clinical Oncology)
ASBMR (American Society for Bone and Mineral Research)
IOF (International Osteoporosis Foundation)

PREMI E RICONOSCIMENTI:

Joint ASCO/AACR Workshop, Methods in Clinical Cancer Research, Vail, Colorado	2000
ESMO Travel Merit Award	2002
Innovators in Breast Cancer Program; Best Poster Award	2004
ESMO Travel Merit Award	2004
Castle Connolly Top Doctors	2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022
Forbes Best Breast Cancer Oncologists	2017

MEMBRO EDITORIAL BOARD:

Journal of Bone Oncology

REVISORE PER LE SEGUENTI RIVISTE SCIENTIFICHE:

Annals of Oncology
Breast Cancer Research and Treatment
British Journal of Cancer
Cancer
Clinical Cancer Research
Critical Reviews in Oncology/Hematology
European Journal of Cancer

Dott.ssa Monica N. Fornier

JAMA
Journal of Clinical Oncology
Oncology
The Lancet

ATTIVITA' SCIENTIFICA:

Principal investigator e co-investigatore di numerosi studi clinici focalizzati sulla valutazione di nuovi farmaci, nonché di studi su farmaci anti-riassorbitivi dell'osso, sulla patogenesi dei loro effetti collaterali, e sugli effetti dei farmaci anti-neoplastici sulla densità ossea.

Autore/co-autore di numerose pubblicazioni.

Autore/co-autore di numerosi abstracts relativi a congressi nazionali e internazionali.

Revisore di riviste scientifiche nazionali e internazionali.

Membro dell' ASCO Educational Book expert panel

Membro dell' "NCCN Task Force Report: Bone Health in Cancer Care" per la delineazione di linee guida sull'utilizzo dei farmaci anti-riassorbimento osseo.

Revisore di grants per il Ministero della Salute - General Directorate for Health and Technological Research.

Revisore di grants per l'Agenzia Italiana del Farmaco (AIFA), programma "Independent research of drugs".

PROTOCOLLI CLINICI E PROGETTI DI RICERCA COME PRINCIPAL INVESTIGATOR:

"A Phase II study of the Epothilone B Analog BMS-247550 in Patients with Taxane-Resistant Metastatic Breast Cancer".

"Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated With Weekly Trastuzumab and Paclitaxel: Association With HER2 Status by Immunohistochemistry and Fluorescent In-situ Hybridization, and With Response Rate"

"A Phase II Study of RO 31-7453 in Patients with Metastatic Breast Cancer Who Have Failed Chemotherapy with both an Anthracycline and a Taxane".

"Incidence of chemotherapy-related amenorrhea in breast cancer patients \leq 40 years of age following taxane-containing adjuvant treatment".

"Clinical protocol for evaluation of the Bayer Advia Centaur HER2/neu assay and the oncogene science microtiter Elisa HER2/neu assay for use in the prediction of response of patients with metastatic breast cancer on Herceptin-based chemotherapies".

"Single Center Open-Label Non-Comparative Phase I Dose Finding Study of Weekly Flavopiridol in Combination with Weekly Docetaxel in Patients with Advanced Solid Tumors"

Dott.ssa Monica N. Fornier

“Pilot study of epirubicin and cyclophosphamide followed by paclitaxel at 10-11 days interval for women with early breast carcinoma”

“A Phase II Trial of Novel Epothilone BMS-247550 in Patients with Advanced Breast Cancer who are Resistant to an Anthracycline, a Taxane, and Capecitabine”.

“A Phase II Study of Trastuzumab in Combination with BMS-247550 in Women with Metastatic Breast Cancer- NCI DFCI #6297”.

“A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy”.

“A Phase II study of bevacizumab with dose dense doxorubicin and cyclophosphamide (AC) followed by dose dense nanoparticle albumin bound paclitaxel for the treatment of early stage breast cancer.”

“A prospective, randomized, double-blind, stratified, placebo-controlled, multi-center, 3-arm trial of the continued efficacy and safety of zoledronic acid (every 4 weeks vs. every 12 weeks vs. placebo) in patients with documented bone metastases from breast cancer”.

”Levels of serum NTX and bone-specific alkaline phosphatase in patients with metastatic cancer, who developed osteonecrosis of the jaw during therapy with bisphosphonates.”

“Identification of potential markers for Osteonecrosis of the Jaw (ONJ): Cross Sectional analysis of gingival crevicular fluid and bone tissue specimens in oncologic patients who developed ONJ compared to control patients”. Project funded by the Clinical and Translational Science Center.

“Metabolic Profiles Evaluated on Serum Samples to Estimate the Risk of Disease Relapse in Early Breast Cancer Patients”. Project funded by the Breast Cancer Research Foundation.

“A phase I-II study of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma”.

“A phase II trial of cabozantinib in women with metastatic hormone-receptor-positive breast cancer with involvement of bone”.

“A case-control pilot study to evaluate the utility of a calcium isotope biomarker, as well as the trabecular bone score (TBS) for the early detection of treatment-related osteoporosis among breast cancer patients receiving adjuvant aromatase inhibitor therapy. “

“A Phase II Randomized, Double-Blind Study Of Neoadjuvant Letrozole Plus Gdc-0032 Versus Letrozole Plus Placebo In Postmenopausal Women With Er-Positive/Her2-Negative, Early Stage Breast Cancer”

“Randomized Phase II Trial of Preoperative Fulvestrant with or without Enzalutamide in ER+/Her2- Breast Cancer”

“Post-menopausal Breast Cancer Patients Treated with Aromatase-inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures after Denosumab Discontinuation”

In aggiunta, partecipazione a numerosi studi di fase I, II, e III come co-investigatore.

LETTURE:

Lecture a congressi nazionali e internazionali.

ELENCO PUBBLICAZIONI:

Peer-Reviewed Articles:

1. Balzarotti M, Santoro A, Tondini C, **Fornier M**, and Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. **Ann Oncol** 1996,7: 970-972.
2. Balzarotti M, Tondini C, Bonfante V, Devizzi L, Viviani S, **Fornier M**, and Santoro A. Lack of carboplatin activity in malignant lymphomas. **Eur J Cancer** 1996, Vol. 32A, No. 13: 2370-2371.
3. Foa P, Pomati M, Ribera S, Caldiera S, Bertoni F, **Fornier M**, and Maiolo AT. Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during Interferon alpha therapy. **Oncol Rep** 1996, 3: 847-849.
4. Foa P, Iurlo A, Da Milano I, Caldiera S, **Fornier M**, Ribera S, Bertoni F, and Maiolo AT. Chronic myeloid leukemia treated with Busulfan: relationship between total amount of drug required during the first year of treatment and duration of chronic phase. **Oncol Rep** 1996, 3: 1067.
5. Foa P, Iurlo A, Orazi A, Saglio G, Ribera S, Bertoni F, Caldiera S, **Fornier M**, and Maiolo AT. Biologic determinants of long term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. **Acta Haematol** 1997, 97:187-188.
6. Tondini C, Balzarotti M, Santoro A, Zanini M, **Fornier M**, Giardini R, DiFelice G, Bozzetti F, and Bonadonna G. Initial chemotherapy for primary resectable large cell lymphoma of the stomach **Ann Oncol** 1997, 8: 497-499.
7. Massaro P, Foa P, Pomati M, LaTargia M, Clerici C, Iurlo A, Caldiera S, **Fornier M**, and Maiolo AT. Polycythemia vera treated with recombinant interferon alpha 2: evidence of a selective effect on the malignant clone. **Am J Hematol** 1997, 56: 126-128.
8. Foa P, Massaro P, Caldiera S, LaTargia M, Iurlo A, Clerici C, **Fornier M**, Bertoni F, and Maiolo AT. Long-term therapeutic efficacy and toxicity of recombinant interferon alpha 2a in polycythemia vera **Eur J Haematol** 1998, 60: 273-277.
9. Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, **Fornier M**, Devizzi L, Verderio P, Valagussa P, and Bonadonna G. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. **Br J Cancer** 1998, 77(6): 992-997.
10. Mauri MC, Bitetto A, Fabiano L, Laini V, Steinhilber C, **Fornier M**, and Rafique F. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. **Prog. Neuro-Psychopharmacol. & Biol. Psychiat** 1999, 23 (1): 43-54.
11. Foa P, **Fornier M**, Miceli R, Seregini E, Santambrogio L, Nosotti M, Massaron S, Cataldo I, Oldani S, Iurlo A, Caldiera S, Bombardieri E. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. **Int J Biol Markers** 1999, 14 (2): 92-98.
12. Foa P, **Fornier M**, Miceli R, Seregini E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E. Tumour markers CEA, NSE, SCC, TPA, and CYFRA 21.1 in resectable non-small cell lung cancer. **Anticancer Res** 1999, 19: 3613-8.

13. Hudis CA, **Fornier M**, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. Five-year results of dose-intensive sequential adjuvant chemotherapy for women with high risk node-positive breast cancer: a phase II study. **J Clin Oncol** 1999, 17 (4): 1118-1126.
14. Mauri MC, Laini V, Barone R, Clemente A, Volontieri LS, Cerveri G, Steinhilber C, **Fornier M**. Postpsychotic depression and residual schizophrenia in a mental health hospital. **Encephale** 2000 26(6):21-26.
15. Seidman AD, **Fornier M**, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas K, Arroyo C, Valero VN, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, Cristofanilli M, Rivera E, Hortobagyi G, Norton L, and Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification **J Clin Oncol** 2001, 15: 2587-2595.
16. **Fornier MN**, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Doxorubicin followed by sequential paclitaxel and cyclophosphamide vs. concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. **Clin Cancer Res** 2001, 7: 3934-3941.
17. Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, **Fornier M**, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. **Clin Cancer Res** 2004, 10 (17): 5754-5761.
18. **Fornier MN**, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated With Weekly Trastuzumab and Paclitaxel: Correlation With HER2 Status by Immunohistochemistry and Fluorescent In-situ Hybridization, and With Response Rate. **Ann Oncol** 2005, 16:234-239.
19. Esteva F, Cheli C, Fritsche H, **Fornier M**, Slamon D, Thiel R, Lueftner D, Ghani F. Clinical Utility of Serum HER-2/neu in Monitoring and Prediction of Progression-free survival in Metastatic Breast Cancer in metastatic breast cancer patients treated with Trastuzumab-based therapies. **Breast Cancer Res** 2005, 7: 436-443.
20. **Fornier MN**, Modi S, Panageas S, Norton L, Hudis C. Incidence of chemotherapy-related long-term amenorrhea in breast cancer patients \leq 40 years of age following adjuvant anthracycline and taxane. **Cancer** 2005, 104 (8):1575-9.
21. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, **Fornier M**, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. **Breast Cancer Res Treat** 2006, 98(3):343-8.
22. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, **Fornier M**, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. **J Am Geriatr Soc** 2006, 54(6):925-31.

23. Hurria A, Hurria A, Zuckerman E, Panageas KS, **Fornier M**, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. *J Am Geriatr Soc* 2006, 54(7):1119-24.
24. Nisticò C, Cuppone F, Bria E, **Fornier M**, Giannarelli D, Mottolese M, Novelli F, Natoli G, Cognetti F, Terzoli E. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. *Anticancer Drugs* 2006, 17(10):1193-200.
25. **Fornier MN**, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C. Increased dose-density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide (EC) followed by paclitaxel, at 10 or 11 day intervals with filgrastim support in women with breast cancer. *Clin Cancer Res* 2007, 13(1):223-7.
26. Stegman LD, Beal KP, Hunt MA, **Fornier MN**, McCormick B. Long-term Clinical Outcomes of Whole-Breast Irradiation Delivered in the Prone Position. *Int J Radiat Oncol Biol Phys* 2007, 68(1):73-81.
27. Bria E, Cuppone F, **Fornier M**, Nisticò C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, Giannarelli D. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. *Breast Cancer Res Treat* 2008, 109 (2): 231-9.
28. Thomas E, Taberero J, **Fornier M**, Conte PF, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Poulart V, Klimovsky J, Lebwohl D, Martin M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. *J Clin Oncol* 2007, 25(23):3399-406.
29. **Fornier M**, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. *Clin Cancer Res* 2007, 13 5841-5846.
30. Dang C, **Fornier M**, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. *J Clin Oncol* 2008, 26(8):1216-22.
31. Ali SM, Carney W, Esteva FJ, **Fornier M**, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A, and the Serum HER-2/neu Study Group. Serum HER-2/neu and Relative Resistance to Trastuzumab-Based Therapy in Metastatic Breast Cancer Patients. *Cancer* 2008, 25; 113(6):1294-1301.
32. Estilo C, **Fornier M**, Farooki A, Carlson D, Bohle G, Huryn JM. Osteonecrosis of the jaw in patients treated with bevacizumab *J Clin Oncol* 2008 20; 26(24):4037-8.
33. Estilo CL, Van Poznak CH, Williams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, **Fornier M**, Halpern JL, Tunick SJ, Huryn JM. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. *Oncologist* 2008, 13(8):911-20.
34. Dang C, D'Andrea G, Lake D, Sugarman S, **Fornier M**, Moynahan ME, Gilewski T, Hurria A, Mills N, Troso-Sandoval T, George R, Robson M, Dickler M, Smith K, Panageas KS, Norton L, Hudis CA.

- Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. **Clin Breast Cancer** 2008, 8(5):418-24.
35. Deng G, Lin H, Seidman A, **Fornier M**, D'Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B. A phase I/II trial of a polysaccharide extract from *Grifola frondosa* (Maitake mushroom) in breast cancer patients: immunological effects. **J Cancer Res Clin Oncol** 2009, 135 (9):1215-21.
36. Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D'Alessandro A, **Fornier M**, Troso-Sandoval T, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. **Breast Cancer Res Treat** 2009, 115(3):609-12.
37. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, **Fornier M**, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. **J Clin Oncol** 2010, 1;28(4):628-33.
38. Damast S, Ho AY, Montgomery L, **Fornier MN**, Ishill N, Elkin E, Beal K, McCormick B. Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated with Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era. **Int J Radiat Oncol Biol Phys** 2010 15;77(4):1105-12.
39. Lin H, de Stanchina E, Zhou XK, Hong F, Seidman A, **Fornier M**, Xiao WL, Kennelly EJ, Wesa K, Cassileth BR, Cunningham-Rundles S. Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. **Cancer Immunol Immunother** 2010, 59(6):885-97
40. Drullinsky P, Sugarman SM, **Fornier MN**, D'Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. **Clin Breast Cancer** 2010, 1;10(6):440-4.
41. Oakman C, Tenori L, Claudino WM, Cappadona S, Nepi S, Battaglia A, Bernini P, Zafarana E, Saccenti E, **Fornier M**, Morris PG, Biganzoli L, Luchinat C, Bertini I, Di Leo A. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. **Ann Oncol** 2011, 22(6):1295-301.
42. **Fornier MN**, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. **Ann Oncol** 2011, 22(12):2575-81.
43. Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, **Fornier MN**. Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. **J Oral Maxillofac Surg**. 2012, 70(12):2768-75.
44. Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, **Fornier M**, Bohle G, Huryn J, Li Y, Doty S, Saxena D. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. **Oral Dis** 2012; 18 (6):602-12.
45. Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, **Fornier MN**. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. **Breast J** 2012, 18(4):345-50.

46. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, **Fornier MN**, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. *Support Care Cancer* 2012; 20(11):2661-8.
47. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, Modi S, **Fornier MN**, Hudis CA, Dannenberg AJ. Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. *Cancer Prev Res (Phila)*. 2013;6(5):428-36.
48. Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, **Fornier M**, Winer EP, Bunnell C, Krop IE. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. *Ann Oncol* 2013;24(7):1841-7.
49. Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, **Fornier M**, Hudis C, Norton L, Luchinat C, Di Leo A. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. *Mol Oncol*. 2014 Aug 10.: S1574-7891(14)
50. Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, **Fornier M**, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. *J Clin Oncol* 2015 Feb 10;33(5):442-7.
51. Iyengar NM, **Fornier MN**, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. *Clin Breast Cancer*. 2016 Apr;16(2):87-94.
52. Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, Farooki A, **Fornier M**, Huryn JM, Estilo CL Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.. *J Craniomaxillofac Surg*. 2016 Mar;44(3):265-70.
53. Veronica Mariotti; David B Page; Oksana Davydov; Didier Hans; Clifford A Hudis; Sujata Patil; Siddharth Kunte; Monica Girotra; Azeez Farooki; **Monica N Fornier**. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: an enhanced screening approach incorporating trabecular bone score. *Journal of Bone Oncology*, 2016 Oct 18;7: 32-37.
54. Freitas-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. *JAMA Dermatol*. 2018 Jun 1;154(6):670-675.
55. P.G. Morris, S Rota, K Cadoo, S Zamora, S Patil, G. D'Andrea, T. Gilewski, J. Bromberg, C. Dang, M. Dickler, S. Modi, A.D. Seidman, N. Sklarin, L Norton, C.A. Hudis, **M.N. Fornier**. Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. *Clinical Breast Cancer*, 2018 Oct;18(5):387-394.
56. Cristina Saura, Evandro de Azambuja, Dominik Hlauschek, Mafalda Oliveira, Dimitrios Zardavas, Anita Jallitsch-Halper, Lorena de la Peña, Paolo Nuciforo, Alberto Ballestrero, Peter Dubsy, Janine M Lombard, Peter Vuylsteke, Carlos Castaneda Altamirano, Cesar Sánchez, Marco Colleoni, Giuliano Santos Borges, Eva Ciruelos, **Monica Fornier**, Katalin Boer, Aditya Bardia, Timothy R. Wilson, Thomas J. Stout, Jerry Y. Hsu, Yi Shi, Martine Piccart, Michael Gnant, José Baselga. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer (LORELEI): a phase 2 randomized, double-blind study. *The Lancet Oncology*, 2019 Sep;20(9):1226-1238.

57. A. McCartney , A. Vignoli , L. Tenori , **M. Fornier** , L. Rossi , E. Risi , C. Luchinat , L. Biganzoli. Metabolomic analysis of serum from patients with early breast cancer may refine 21-gene expression assay risk recurrence stratification. **NPJ Breast Cancer**, 2019 Aug 29;5:26.
58. Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, **Fornier MN**, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner GA, Jochelson M, Norton L, Hudis CA, Dang CT. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. **JAMA Netw Open**. 2019 Nov 1;2(11).
59. Krebs S, Veach DR, Carter LM, Grkovski M, **Fornier M**, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS. First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography. **J Nucl Med**. 2020 Mar 13;jnumed.119.234864. doi: 10.2967/jnumed.119.234864.
60. Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, **Fornier M**, Mahmood U, Baselga J, Yeap BY, Chabner BA, Isakoff SJ. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. **Oncologist**. 2020 May 28. doi: 10.1634/theoncologist.2020-0127.
61. Montagna G, Sevilimedu V, **Fornier M**, Jhaveri K, Morrow M, Pilewskie ML. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery? **Ann Surg Oncol**. 2020 Nov;27(12):4702-4710.
62. Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, **Fornier M**, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Measuring Tumor Epichaperome Expression Using [¹²⁴I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. **JCO Precis Oncol**. 2020 Nov 17;4.
63. Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, **Fornier MN**, Sklarin NT, Chandarlapaty S, Modi S. A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with *PIK3CA*-Mutated HER2-Positive Metastatic Breast Cancer. **Clin Cancer Res**. 2021 Jul 15;27(14):3867-3875.
64. Botty van den Bruele A, Ferraro E, Sevilimedu V, Hogan MP, Javed-Tayyab S, Le T, **Fornier MN**, Morrow M, Sacchini V. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? **Breast Cancer Res Treat**. 2021 Sep;189(2):307-315.
65. Yeung M, Ho K, **Fornier MN**, Farooki A. Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience. **HSS J**. 2021 Jul;17(2):185-191.

Books, book chapters and reviews:

1. Iurlo A, **Fornier M**, Caldiera S, Bertoni F, and Foa P. Palmar-plantar erythrodysesthesia syndrome due to 5-Fluorouracil therapy: and underestimated toxic event? **Acta Oncol** 1997, 36: 653-654.
2. Seidman AD, **Fornier M**, Hudis C. Taxanes in combination chemotherapy regimens for treatment of breast cancer. **Current Practice Medicine**, Vol 2, Number 1, 1999.

3. **Fornier M**, Munster P, and Seidman AD. An update on the management of advanced breast cancer **Oncology**, 1999, Vol 13, No 5: 647-658.
4. Seidman AD, **Fornier M**, Theodoulou M, Surbone A, Moynahan ME, Currie V, Moasser M, Arroyo C, Chin J, Bach A, Denton C, Reuter V, Norton L, Hudis C Weekly one-hour paclitaxel plus trastuzumab for metastatic breast cancer. **Oncology** 1999 13(12) Suppl.7.
5. **Fornier M**, and Seidman AD. Herceptin: efficacy and safety in combination with taxanes. **Biol Ther Breast Cancer** 2000, 2:6-10.
6. **Fornier M**, Esteva FJ, and Seidman AD. Herceptin in combination with chemotherapy for the treatment of metastatic breast cancer. **Semin Oncol** 2000 27(6): 38-45.
7. Crucitta E, **Fornier MN**, Locopo N, Silvestris N, Lorusso V, De Lena M. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer. **Int J Oncol**, 2002 20(6):1283-8.
8. **Fornier M**, Hudis C. Treatment Guidelines for Breast Cancer. **Oncology Special Edition** 2002 Vol 5: 13-26.
9. Van Poznak C, **Fornier M**, Munster P, Seidman AD. **Breast Cancer Therapy Annual** Chapter "Novel Chemotherapeutic Agents for Breast Cancer". Martin Dunitz Publishers, London, UK, 2002.
10. **Fornier M**, Risio M, Van Poznak C, Seidman A. HER2 Testing and Correlation with Efficacy of Trastuzumab Therapy. **Oncology** 2002 16 (10): 1340-1348.
11. Dang CT, **Fornier MN**, Hudis CA. Risk models for neutropenia in patients with breast cancer. **Oncology (Huntingt)** 2003, 17 (Suppl 11):14-20.
12. Wheler J, **Fornier M**, Seidman A. Treatment of hormone-refractory metastatic breast cancer: a critical review. **Tumori** 2004, Vol 90, No. 5.
13. Modi S, **Fornier MN**, Seidman A. Combination Cancer Therapy. Modulators and Potentiators. Development of Inhibitors of HER2 with Taxanes: New Directions in Breast Cancer Therapy. Humana Press. Book Chapter pps: 175-196; 2004.
14. **Fornier M**, Hudis C. Adjuvant Chemotherapy of Primary Breast Cancer. **Curr Oncol Rep**, 2005 Jan; 7(1):18-22.
15. **Fornier M**, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. **Breast Cancer Res** 2005, 7(2):64-69.
16. *Consensus conference on breast conservation. Consensus Conference Committee. **J Am Coll Surg** 2006, 203(2):198-207.
17. *Consensus conference on breast conservation, Milan, Italy, April 28-May 1, 2005. Consensus Conference Committee. **Breast J** 2006, 12(4):398-407.
18. *Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy. Conference Committee. **Cancer** 2006, 107(2):242-50.

**2005 Breast Consensus Conference Committee: Gordon F. Schwartz; Umberto Veronesi; Harry Bartelink; Luigi Cataliotti; Krishna B. Clough; Domenico M. D'Ugo; J. M. Dixon; Ian S. Fentiman; Monica Fornier; Alain Fourquet; Oreste Gentilini; Sylvia H. Heywang-Köbrunner; Roland Holland; Kevin S. Hughes; Vincenzo Lattanzio; Beryl McCormick; Robert E. Mansel; Richard Margolese; Shahla Masood; Ellen B. Mendelson; Ivo A. Olivotto; Juan P. Palazzo; Lori J. Pierce; Christopher J. Poole; Emiel J. Th. Rutgers; Lawrence J. Solin; Fattaneh Tavassoli; Daniela A. Terribile; Michael Untch.*

19. **Fornier M.** Epothilones in Breast Cancer: Review of Clinical Experience. **Ann Oncol**, 2007 18: v16-v21.
20. **Fornier M.** Ixabepilone, first in a new class of antineoplastics, the natural epothilones and their analogs. **Clinical Breast Cancer** 2007, Oct;7 (10):757-63.
21. Farooki A, **Fornier M**, Girotra M. Anabolic therapies for osteoporosis. **N Engl J Med** 2007, 357(23):2410-1
22. Atzori F, **Fornier M.** Epothilones in breast cancer: current status and future directions. **Expert Rev Anticancer Ther**, 2008 (8):1299-311.
23. Morris PG, **Fornier M.** Microtubule active agents **Clin Cancer Res** 2008, 15;14(22):7167-72.
24. Morris PG, **Fornier MN.** Novel anti-tubulin cytotoxic agents for breast cancer. **Expert Rev Anticancer Ther** 2009, 9(2):175-85.
25. Gralow JR, Biermann JS, Farooki A, **Fornier MN**, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. **J Natl Compr Canc Netw** 2009, 7 Suppl 3:S1-S32.
26. Morris PG, **Fornier MN.** Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer. **Clin Adv Hematol Oncol.** 2009, 7(2):115-22.
27. Schiavon G, Maki RG, **Fornier M.** GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. **Curr Cancer Ther Rev** 2009, 100-104(5).
28. Morris PG, **Fornier MN.** Optimizing the use of anthracyclines in older patients with breast cancer. **Crit Rev Oncol Hematol** 2011, 77(2):131-41.
29. Murphy CG, **Fornier MN.** HER2 positive breast cancer: beyond trastuzumab. **Oncology (Williston Park).** 2010, 30; 24(5):410-5.
30. Comen E, **Fornier MN.** Algorithms for Treatment of Patients with Pretreated Metastatic Breast Cancer with Prior Exposure to Taxanes and Anthracyclines. **Clin Breast Cancer** 2010, 10 Suppl 2:S7-19.
31. **Fornier M.** Denosumab: the second chapter in treating bone metastases or a new book? **J Clin Oncol** 2010, 28(35):5127-31.
32. **Fornier MN.** Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. **Clin Breast Cancer** 2010, 1;10(5):352-8.
33. **Fornier MN.** Approved agents for metastatic breast cancer. **Semin Oncol** 2011;38 Suppl 2:S3-10.
34. **Fornier M**, Fumoleau P. The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment. **Breast J** 2012, 18(1):41-51.

35. Twelves CJ, **Fornier MN**. Managing patients with heavily pre-treated metastatic breast cancer: balancing efficacy and safety. **Comm Oncol** 2012, 9: 5s.
36. Gralow JR, Biermann JS, Farooki A, **Fornier MN**, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. **J Natl Compr Canc Netw**. 2013;11 Suppl 3:S1-S50.
37. Cadoo KA, **Fornier MN**, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. **Q J Nucl Med Mol Imaging**. 2013;57(4):312-21.
38. Farooki A, **Fornier M**, Boland P. Atypical femur fractures associated with use of bisphosphonates and denosumab. **Ann Oncol**. 2015 Apr;26(4):819-20.
39. Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials. Ramnaraign B, Page D, **Fornier M**. **Breast Cancer Manag**. 2015 4 (3), 135-144.
40. Denosumab and fracture risk in women with breast cancer. Farooki A, **Fornier M**. **Lancet** 2015 Nov 21;386(10008):2056-7.
41. Less Intense Dosing Schedule for a Bone-Modifying Agent. **Fornier MN**. **JAMA Oncol**. 2017; Jul 1;3(7):893-894.
42. Ferraro E, **Fornier MN**. Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy. **Ann Transl Med**. 2020 Dec;8(24):1694. doi: 10.21037/atm-20-5406.

Monica N. Fornier, M.D.

24/7/22
Monica Fornier

CURRICULUM VITAE

NAME: MONICA N. FORNIER

CITIZENSHIP: Italian and U.S.

LICENSED PHYSICIAN: U.S. Medical License Year: 2000 Place: New York
European Medical License Year: 1992 Place: Milan

BOARD CERTIFICATION:
Year: 1992 Name: European Board Certification in Internal Medicine
Year: 1998 Name: European Board Certification in Medical Oncology

EDUCATIONAL BACKGROUND:

<u>INSTITUTION</u>	<u>DEGREE</u>	<u>YEARS</u>
Memorial Sloan-Kettering Cancer Center, New York, NY	Fellowship in Oncology	1998-2001
University of Milan School of Medicine, Milan Italy	Specialty in Oncology Summa Cum Laude	1994-1998
Clinical Research Fellowship "INT-AIRC", Istituto Nazionale Tumori, Milan, Italy		1993-1994
Clinical Research Fellowship "Marco Semenza", Istituto Nazionale Tumori, Milan, Italy		1992-1993
University of Milan School of Medicine, Milan Italy	Medical Degree Summa Cum Laude (110 cum laude/110)	1992

POSITIONS AND APPOINTMENTS

Associate Member, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY	2013 – present
Associate Professor of Medicine Weill Cornell Medical College, New York, NY	2013- present
Assistant Member, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY	2005- 2013

Monica N. Fournier, M.D.

Assistant Member I, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY	2004- 2005
Assistant Professor of Medicine Weill Cornell Medical College, New York, NY	2006-2013
Clinical Assistant Physician, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY	2001-2004
Instructor in Medicine, Department of Medicine, Weill Cornell Medical College, New York, NY	2001-2006

LANGUAGES:

Spoken: Italian (native language), English, French, German.

Written: Italian (native language), English, French, German.

CLINICAL ACTIVITY:

Clinical activity for oncology outpatients and inpatients at the Breast Medicine Service of Memorial Sloan-Kettering Cancer Center.

TEACHING ACTIVITY:

2014 - 2016: University of Milan, Visiting Professor for the School of Specialty of Medical Oncology; lectures on ASCO review and breast cancer therapy.

Teaching and mentoring to medical students, residents and fellows both at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College.

Teaching at the "Memorial Sloan-Kettering Course for the Salzburg Medical Seminars International." Salzburg, Austria.

ADMINISTRATIVE ACTIVITY:

2005-2007: Member of the committee "Junior Faculty Council" for the mentorship of fellows and junior faculty members.

2003- 2014: Member of the "Pregnancy Policy Committee" to create a hospital algorithm to ensure that a pregnancy test is obtained prior to any medical procedure.

2008 - present: Member of the National Comprehensive Cancer Network (NCCN) Bone Health in Cancer Care Task Force, to create guidelines for the optimal use of bone-modifying agents.

2009-present: member of the Adult Translational Research Advisory Committee, as a grant reviewer for the Clinical and Translational Science Center (CTSC), which includes Weill Cornell Medical College and Graduate School, Cornell Ithaca, Cornell Cooperative Extension, NYC, Hunter College Gene Center and Nursing School, Hospital for Special Surgery and Memorial Sloan-Kettering Cancer Center.

2021-present: member of Research Council Committee at MSKCC.

Monica N. Fornier, M.D.

SCIENTIFIC AND MEDICAL SOCIETIES:

ASCO (American Society of Clinical Oncology)
ESMO (European Society of Clinical Oncology)
ASBMR (American Society for Bone and Mineral Research)
IOF (International Osteoporosis Foundation)

HONORS AND AWARDS:

<i>Name:</i>	<i>Date:</i>
Joint ASCO/AACR Workshop, Methods in Clinical Cancer Research, Vail, Colorado	2000
ESMO Travel Merit Award	2002
Innovators in Breast Cancer Program; Best Poster Award	2004
ESMO Travel Merit Award	2004
Castle Connelly Top Doctors	2012; 2013; 2014;2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022
Forbes Best Breast Cancer Oncologists	2017

EDITORIAL BOARD MEMBER:

Journal of Bone Oncology

AD HOC JOURNAL REVIEWER:

Annals of Oncology
Breast Cancer Research and Treatment
British Journal of Cancer
Cancer
Clinical Cancer Research
Critical Reviews in Oncology/Hematology
European Journal of Cancer
JAMA
Journal of Clinical Oncology
Oncology
The Lancet

GRANT REVIEWER:

2009-present: member of the Adult Translational Research Advisory Committee, as a grant reviewer for the Clinical and Translational Science Center (CTSC), which includes Weill Cornell Medical College and Graduate School, Cornell Ithaca, Cornell Cooperative Extension, NYC, Hunter College Gene Center and Nursing School, Hospital for Special Surgery and Memorial Sloan-Kettering Cancer Center.

Monica N. Fornier, M.D.

2011: grant reviewer for the Italian Medicine Agency (Agenzia Italiana del Farmaco -AIFA), program "Independent research of drugs".

2010-present: grant reviewer for the Italian Ministry of Health, General Directorate for Health and Technological Research.

RESEARCH ACTIVITY:

Principal investigator and co-investigator of clinical trials assessing novel agents for the treatment of breast carcinoma, as well as trials with bone-modifying agents, and studying the pathogenesis of side effects of such agents. Additionally, investigator in assessing the effect of breast cancer therapeutics on women's bone health.

CLINICAL TRIALS AND RESEARCH PROJECTS AS PRINCIPAL INVESTIGATOR:

"A Phase II study of the Epothilone B Analog BMS-247550 in Patients with Taxane-Resistant Metastatic Breast Cancer".

"Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated With Weekly Trastuzumab and Paclitaxel: Association With HER2 Status by Immunohistochemistry and Fluorescent In-situ Hybridization, and With Response Rate"

"A Phase II Study of RO 31-7453 in Patients with Metastatic Breast Cancer Who Have Failed Chemotherapy with both an Anthracycline and a Taxane".

"Incidence of chemotherapy-related amenorrhea in breast cancer patients ≤ 40 years of age following taxane-containing adjuvant treatment".

"Clinical protocol for evaluation of the Bayer Advia Centaur HER2/neu assay and the oncogene science microtiter Elisa HER2/neu assay for use in the prediction of response of patients with metastatic breast cancer on Herceptin-based chemotherapies".

"Single Center Open-Label Non-Comparative Phase I Dose Finding Study of Weekly Flavopiridol in Combination with Weekly Docetaxel in Patients with Advanced Solid Tumors"

"Pilot study of epirubicin and cyclophosphamide followed by paclitaxel at 10-11 days interval for women with early breast carcinoma"

"A Phase II Trial of Novel Epothilone BMS-247550 in Patients with Advanced Breast Cancer who are Resistant to an Anthracycline, a Taxane, and Capecitabine".

"A Phase II Study of Trastuzumab in Combination with BMS-247550 in Women with Metastatic Breast Cancer- NCI DFCI #6297".

"A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy".

"A Phase II study of bevacizumab with dose dense doxorubicin and cyclophosphamide (AC) followed by dose dense nanoparticle albumin bound paclitaxel for the treatment of early stage breast cancer."

Monica N. Fornier, M.D.

“A prospective, randomized, double-blind, stratified, placebo-controlled, multi-center, 3-arm trial of the continued efficacy and safety of zoledronic acid (every 4 weeks vs. every 12 weeks vs. placebo) in patients with documented bone metastases from breast cancer”.

”Levels of serum NTX and bone-specific alkaline phosphatase in patients with metastatic cancer, who developed osteonecrosis of the jaw during therapy with bisphosphonates.”

“Identification of potential markers for Osteonecrosis of the Jaw (ONJ): Cross Sectional analysis of gingival crevicular fluid and bone tissue specimens in oncologic patients who developed ONJ compared to control patients”. Project funded by the Clinical and Translational Science Center.

“Metabolic Profiles Evaluated on Serum Samples to Estimate the Risk of Disease Relapse in Early Breast Cancer Patients”. Project funded by the Breast Cancer Research Foundation.

“A phase I-II study of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma”.

“A phase II trial of cabozantinib in women with metastatic hormone-receptor-positive breast cancer with involvement of bone”.

“A case-control pilot study to evaluate the utility of a calcium isotope biomarker, as well as the trabecular bone score (TBS) for the early detection of treatment-related osteoporosis among breast cancer patients receiving adjuvant aromatase inhibitor therapy. “

“A Phase II Randomized, Double-Blind Study Of Neoadjuvant Letrozole Plus Gdc-0032 Versus Letrozole Plus Placebo In Postmenopausal Women With Er-Positive/Her2-Negative, Early Stage Breast Cancer”

“Randomized Phase II Trial of Preoperative Fulvestrant with or without Enzalutamide in ER+/Her2- Breast Cancer”

“Post-menopausal Breast Cancer Patients Treated with Aromatase-inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures after Denosumab Discontinuation”

In addition, participation to numerous phase I, II and III clinical trials as co-investigator.

LECTURES:

Lectures to national and international congresses.

BIBLIOGRAPHY

Peer-Reviewed Articles:

1. Balzarotti M, Santoro A, Tondini C, **Fornier M**, and Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. *Ann Oncol* 1996;7: 970-972.
2. Balzarotti M, Tondini C, Bonfante V, Devizzi L, Viviani S, **Fornier M**, and Santoro A. Lack of carboplatin activity in malignant lymphomas. *Eur J Cancer* 1996, Vol. 32A, No. 13: 2370-2371.
3. Foa P, Pomati M, Ribera S, Caldiera S, Bertoni F, **Fornier M**, and Maiolo AT. Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during Interferon alpha therapy. *Oncol Rep* 1996, 3: 847-849.

Monica N. Fornier, M.D.

4. Foa P, Iurlo A, Da Milano I, Caldiera S, **Fornier M**, Ribera S, Bertoni F, and Maiolo AT. Chronic myeloid leukemia treated with Busulfan: relationship between total amount of drug required during the first year of treatment and duration of chronic phase. **Oncol Rep** 1996, 3: 1067.
5. Foa P, Iurlo A, Orazi A, Saglio G, Ribera S, Bertoni F, Caldiera S, **Fornier M**, and Maiolo AT. Biologic determinants of long term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. **Acta Haematol** 1997, 97:187-188.
6. Tondini C, Balzarotti M, Santoro A, Zanini M, **Fornier M**, Giardini R, DiFelice G, Bozzetti F, and Bonadonna G. Initial chemotherapy for primary resectable large cell lymphoma of the stomach **Ann Oncol** 1997, 8: 497-499.
7. Massaro P, Foa P, Pomati M, LaTargia M, Clerici C, Iurlo A, Caldiera S, **Fornier M**, and Maiolo AT. Polycythemia vera treated with recombinant interferon alpha 2: evidence of a selective effect on the malignant clone. **Am J Hematol** 1997, 56: 126-128.
8. Foa P, Massaro P, Caldiera S, LaTargia M, Iurlo A, Clerici C, **Fornier M**, Bertoni F, and Maiolo AT. Long-term therapeutic efficacy and toxicity of recombinant interferon alpha 2a in polycythemia vera **Eur J Haematol** 1998, 60: 273-277.
9. Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, **Fornier M**, Devizzi L, Verderio P, Valagussa P, and Bonadonna G. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. **Br J Cancer** 1998, 77(6): 992-997.
10. Mauri MC, Bitetto A, Fabiano L, Laini V, Steinhilber C, **Fornier M**, and Rafique F. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. **Prog. Neuro-Psychopharmacol. & Biol. Psychiat** 1999, 23 (1): 43-54.
11. Foa P, **Fornier M**, Miceli R, Seregini E, Santambrogio L, Nosotti M, Massaron S, Cataldo I, Oldani S, Iurlo A, Caldiera S, Bombardieri E. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. **Int J Biol Markers** 1999, 14 (2): 92-98.
12. Foa P, **Fornier M**, Miceli R, Seregini E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E. Tumour markers CEA, NSE, SCC, TPA, and CYFRA 21.1 in resectable non-small cell lung cancer. **Anticancer Res** 1999, 19: 3613-8.
13. Hudis CA, **Fornier M**, Riccio L, Lebwahl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. Five-year results of dose-intensive sequential adjuvant chemotherapy for women with high risk node-positive breast cancer: a phase II study. **J Clin Oncol** 1999, 17 (4): 1118-1126.
14. Mauri MC, Laini V, Barone R, Clemente A, Volontieri LS, Cerveri G, Steinhilber C, **Fornier M**. Postpsychotic depression and residual schizophrenia in a mental health hospital. **Encephale** 2000 26(6):21-26.
15. Seidman AD, **Fornier M**, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas K, Arroyo C, Valero VN, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, Cristofanilli M, Rivera E, Hortobagyi G, Norton L, and Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification **J Clin Oncol** 2001, 15: 2587-2595.

16. **Fornier MN**, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Doxorubicin followed by sequential paclitaxel and cyclophosphamide vs. concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. **Clin Cancer Res** 2001, 7: 3934-3941.
17. Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, **Fornier M**, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. **Clin Cancer Res** 2004, 10 (17): 5754-5761.
18. **Fornier MN**, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated With Weekly Trastuzumab and Paclitaxel: Correlation With HER2 Status by Immunohistochemistry and Fluorescent In-situ Hybridization, and With Response Rate. **Ann Oncol** 2005, 16:234-239.
19. Esteva F, Cheli C, Fritsche H, **Fornier M**, Slamon D, Thiel R, Lueftner D, Ghani F. Clinical Utility of Serum HER-2/neu in Monitoring and Prediction of Progression-free survival in Metastatic Breast Cancer in metastatic breast cancer patients treated with Trastuzumab-based therapies. **Breast Cancer Res** 2005, 7: 436-443.
20. **Fornier MN**, Modi S, Panageas S, Norton L, Hudis C. Incidence of chemotherapy-related long-term amenorrhea in breast cancer patients ≤ 40 years of age following adjuvant anthracycline and taxane. **Cancer** 2005, 104 (8):1575-9.
21. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, **Fornier M**, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. **Breast Cancer Res Treat** 2006, 98(3):343-8.
22. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, **Fornier M**, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. **J Am Geriatr Soc** 2006, 54(6):925-31.
23. Hurria A, Hurria A, Zuckerman E, Panageas KS, **Fornier M**, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. **J Am Geriatr Soc** 2006, 54(7):1119-24.
24. Nisticò C, Cuppone F, Bria E, **Fornier M**, Giannarelli D, Mottolese M, Novelli F, Natoli G, Cognetti F, Terzoli E. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. **Anticancer Drugs** 2006, 17(10):1193-200.
25. **Fornier MN**, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C. Increased dose-density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide (EC) followed by paclitaxel, at 10 or 11 day intervals with filgrastim support in women with breast cancer. **Clin Cancer Res** 2007,1 ;13(1):223-7.
26. Stegman LD, Beal KP, Hunt MA, **Fornier MN**, McCormick B. Long-term Clinical Outcomes of Whole-Breast Irradiation Delivered in the Prone Position. **Int J Radiat Oncol Biol Phys** 2007, 1;68(1):73-81.

27. Bria E, Cuppone F, **Fornier M**, Nisticò C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, Giannarelli D. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. **Breast Cancer Res Treat** 2008, 109 (2): 231-9.
28. Thomas E, Tabernero J, **Fornier M**, Conte PF, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Poulart V, Klimovsky J, Lebwohl D, Martin M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. **J Clin Oncol** 2007, 10;25 (23):3399-406.
29. **Fornier M**, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. **Clin Cancer Res** 2007, 13 5841-5846.
30. Dang C, **Fornier M**, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. **J Clin Oncol** 2008, 10;26(8):1216-22
31. Ali SM, Carney W, Esteva FJ, **Fornier M**, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A, and the Serum HER-2/neu Study Group. Serum HER-2/neu and Relative Resistance to Trastuzumab-Based Therapy in Metastatic Breast Cancer Patients. **Cancer** 2008, 25; 113(6):1294-1301.
32. Estilo C, **Fornier M**, Farooki A, Carlson D, Bohle G, Huryn JM. Osteonecrosis of the jaw in patients treated with bevacizumab **J Clin Oncol** 2008 20; 26(24):4037-8.
33. Estilo CL, Van Poznak CH, Williams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, **Fornier M**, Halpern JL, Tunick SJ, Huryn JM. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. **Oncologist** 2008, 13(8):911-20.
34. Dang C, D'Andrea G, Lake D, Sugarman S, **Fornier M**, Moynahan ME, Gilewski T, Hurria A, Mills N, Troso-Sandoval T, George R, Robson M, Dickler M, Smith K, Panageas KS, Norton L, Hudis CA. Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. **Clin Breast Cancer** 2008, 8(5):418-24.
35. Deng G, Lin H, Seidman A, **Fornier M**, D'Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B. A phase I/II trial of a polysaccharide extract from *Grifola frondosa* (Maitake mushroom) in breast cancer patients: immunological effects. **J Cancer Res Clin Oncol** 2009, 135 (9):1215-21.
36. Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D'Alessandro A, **Fornier M**, Troso-Sandoval T, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. **Breast Cancer Res Treat** 2009, 115(3):609-12.

37. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, **Fornier M**, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. **J Clin Oncol** 2010, 1;28(4):628-33.
38. Damast S, Ho AY, Montgomery L, **Fornier MN**, Ishill N, Elkin E, Beal K, McCormick B. Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated with Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era. **Int J Radiat Oncol Biol Phys** 2010 15;77(4):1105-12.
39. Lin H, de Stanchina E, Zhou XK, Hong F, Seidman A, **Fornier M**, Xiao WL, Kennelly EJ, Wesa K, Cassileth BR, Cunningham-Rundles S. Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. **Cancer Immunol Immunother** 2010, 59(6):885-97
40. Drullinsky P, Sugarman SM, **Fornier MN**, D'Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. **Clin Breast Cancer** 2010, 1;10(6):440-4.
41. Oakman C, Tenori L, Claudino WM, Cappadona S, Nepi S, Battaglia A, Bernini P, Zafarana E, Saccenti E, **Fornier M**, Morris PG, Biganzoli L, Luchinat C, Bertini I, Di Leo A. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. **Ann Oncol** 2011, 22(6):1295-301.
42. **Fornier MN**, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. **Ann Oncol** 2011, 22(12):2575-81.
43. Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, **Fornier MN**. Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. **J Oral Maxillofac Surg**. 2012, 70(12):2768-75.
44. Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, **Fornier M**, Bohle G, Huryn J, Li Y, Doty S, Saxena D. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. **Oral Dis** 2012; 18 (6):602-12.
45. Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, **Fornier MN**. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. **Breast J** 2012, 18(4):345-50.
46. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, **Fornier MN**, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. **Support Care Cancer** 2012; 20(11):2661-8.
47. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, Modi S, **Fornier MN**, Hudis CA, Dannenberg AJ. Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. **Cancer Prev Res (Phila)**. 2013;6(5):428-36.
48. Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, **Fornier M**, Winer EP, Bunnell C, Krop IE. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. **Ann Oncol** 2013;24 (7):1841-7.

49. Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, **Fornier M**, Hudis C, Norton L, Luchinat C, Di Leo A. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. **Mol Oncol**. 2014 Aug 10.: S1574-7891(14)
50. Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, **Fornier M**, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. **J Clin Oncol** 2015 Feb 10;33(5):442-7.
51. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer . Iyengar NM, **Fornier MN**, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT. **Clin Breast Cancer**. 2016 Apr;16(2):87-94.
52. Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, Farooki A, **Fornier M**, Huryn JM, Estilo CL Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.. **J Craniomaxillofac Surg**. 2016 Mar;44(3):265-70.
53. Veronica Mariotti; David B Page; Oksana Davydov; Didier Hans; Clifford A Hudis; Sujata Patil; Siddharth Kunte; Monica Girotra; Azeez Farooki; **Monica N Fornier**. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: an enhanced screening approach incorporating trabecular bone score. **Journal of Bone Oncology**, 2016 Oct 18;7: 32-37.
54. Freitas-Martinez A, Shapiro J, Chan D, **Fornier M**, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. **JAMA Dermatol**. 2018 Jun 1;154(6):670-675.
55. . P.G. Morris, S Rota, K Cadoo, S Zamora, S Patil, G. D'Andrea, T. Gilewski, J. Bromberg, C. Dang, M. Dickler, S. Modi, A.D. Seidman, N. Sklarin, L Norton, C.A. Hudis, **M.N. Fornier**. Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer **Clinical Breast Cancer**, 2018 Oct;18(5):387-394.
56. C. Saura, E. de Azambuja, D. Hlauschek, M. Oliveira, D. Zardavas, A. Jallitsch-Halper, L. de la Peña, P. Nuciforo, A. Ballestrero, P. Dubsy, J. M Lombard, P. Vuylsteke, C. Castaneda Altamirano, C. Sánchez, M. Colleoni, G. Santos Borges, E. Ciruelos, **M. Fornier**, K. Boer, A. Bardia, T. R. Wilson, T. J. Stout, J.Y. Hsu, Yi Shi, M. Piccart, M. Gnant,, J. Baselga. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer (LORELEI): a phase 2 randomized, double-blind study. **Lancet Oncology**, 2019 Sep;20(9):1226-1238.
57. A. McCartney , A. Vignoli , L. Tenori , **M. Fornier** , L. Rossi , E. Risi , C. Luchinat , L. Biganzoli. Metabolomic analysis of serum from patients with early breast cancer may refine 21-gene expression assay risk recurrence stratification. **NPJ Breast Cancer**, 2019 Aug 29;5:26.
58. Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, **Fornier MN**, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner GA, Jochelson M, Norton L, Hudis CA, Dang CT. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. **JAMA Netw Open**. 2019 Nov 1;2(11).
59. Krebs S, Veach DR, Carter LM, Grkovski M, **Fornier M**, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS.

- First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography. *J Nucl Med*. 2020 Mar 13;jnumed.119.234864. doi: 10.2967/jnumed.119.234864. Online ahead of print.PMID: 32169913
60. Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, **Fornier M**, Mahmood U, Baselga J, Yeap BY, Chabner BA, Isakoff SJ. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. *Oncologist*. 2020 May 28;25(8):652-60. doi: 10.1634/theoncologist.2020-0127.
61. Montagna G, Sevilimedu V, **Fornier M**, Jhaveri K, Morrow M, Pilewskie ML. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery? *Ann Surg Oncol*. 2020 Nov;27(12):4702-4710.
62. Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, **Fornier M**, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Measuring Tumor Epichaperome Expression Using [¹²⁴I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. *JCO Precis Oncol*. 2020 Nov 17;4.
63. Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, **Fornier MN**, Sklarin NT, Chandarlapaty S, Modi S. A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with *PIK3CA*-Mutated HER2-Positive Metastatic Breast Cancer. *Clin Cancer Res*. 2021 Jul 15;27(14):3867-3875.
64. Botty van den Bruele A, Ferraro E, Sevilimedu V, Hogan MP, Javed-Tayyab S, Le T, **Fornier MN**, Morrow M, Sacchini V. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? *Breast Cancer Res Treat*. 2021 Sep;189(2):307-315.
65. Yeung M, Ho K, **Fornier MN**, Farooki A. Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience. *HSS J*. 2021 Jul;17(2):185-191.

Books, book chapters and reviews:

1. Iurlo A, **Fornier M**, Caldiera S, Bertoni F, and Foa P. Palmar-plantar erythrodysesthesia syndrome due to 5-Fluorouracil therapy: and underestimated toxic event? *Acta Oncol* 1997, 36: 653-654.
2. Seidman AD, **Fornier M**, Hudis C. Taxanes in combination chemotherapy regimens for treatment of breast cancer. *Current Practice Medicine*, Vol 2, Number 1, 1999.
3. **Fornier M**, Munster P, and Seidman AD. An update on the management of advanced breast cancer *Oncology*, 1999, Vol 13, No 5: 647-658.
4. Seidman AD, **Fornier M**, Theodoulou M, Surbone A, Moynahan ME, Currie V, Moasser M, Arroyo C, Chin J, Bach A, Denton C, Reuter V, Norton L, Hudis C Weekly one-hour paclitaxel plus trastuzumab for metastatic breast cancer. *Oncology* 1999 13(12) Suppl.7.
5. **Fornier M**, and Seidman AD. Herceptin: efficacy and safety in combination with taxanes. *Biol Ther Breast Cancer* 2000, 2:6-10.

6. **Fornier M**, Esteva FJ, and Seidman AD. Herceptin in combination with chemotherapy for the treatment of metastatic breast cancer. **Semin Oncol** 2000 27(6): 38-45.
 7. Crucitta E, **Fornier MN**, Locopo N, Silvestris N, Lorusso V, De Lena M. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer. **Int J Oncol**, 2002 20(6):1283-8.
 8. **Fornier M**, Hudis C. Treatment Guidelines for Breast Cancer. **Oncology Special Edition** 2002 Vol 5: 13-26.
 9. Van Poznak C, **Fornier M**, Munster P, Seidman AD. **Breast Cancer Therapy Annual** Chapter "Novel Chemotherapeutic Agents for Breast Cancer". Martin Dunitz Publishers, London, UK, 2002.
 10. **Fornier M**, Risio M, Van Poznak C, Seidman A. HER2 Testing and Correlation with Efficacy of Trastuzumab Therapy. **Oncology** 2002 16 (10): 1340-1348.
 11. Dang CT, **Fornier MN**, Hudis CA. Risk models for neutropenia in patients with breast cancer. **Oncology** (Huntingt) 2003, 17 (Suppl 11):14-20.
 12. Wheler J, **Fornier M**, Seidman A. Treatment of hormone-refractory metastatic breast cancer: a critical review. **Tumori** 2004, Vol 90, No. 5.
 13. Modi S, **Fornier MN**, Seidman A. Combination Cancer Therapy. Modulators and Potentiators. Development of Inhibitors of HER2 with Taxanes: New Directions in Breast Cancer Therapy. Humana Press. Book Chapter pps: 175-196; 2004.
 14. **Fornier M**, Hudis C. Adjuvant Chemotherapy of Primary Breast Cancer. **Curr Oncol Rep**, 2005 Jan; 7(1):18-22.
 15. **Fornier M**, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. **Breast Cancer Res** 2005, 7(2):64-69.
 16. *Consensus conference on breast conservation. Consensus Conference Committee. **J Am Coll Surg** 2006, 203(2):198-207.
 17. *Consensus conference on breast conservation, Milan, Italy, April 28-May 1, 2005. Consensus Conference Committee. **Breast J** 2006, 12(4):398-407.
 18. *Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy. Conference Committee. **Cancer** 2006, 107(2):242-50.
- *2005 Breast Consensus Conference Committee: Gordon F. Schwartz; Umberto Veronesi; Harry Bartelink; Luigi Cataliotti; Krishna B. Clough; Domenico M. D'Ugo; J. M. Dixon; Ian S. Fentiman; Monica Fornier; Alain Fourquet; Oreste Gentilini; Sylvia H. Heywang-Köbrunner; Roland Holland; Kevin S. Hughes; Vincenzo Lattanzio; Beryl McCormick; Robert E. Mansel; Richard Margolese; Shahla Masood; Ellen B. Mendelson; Ivo A. Olivotto; Juan P. Palazzo; Lori J. Pierce; Christopher J. Poole; Emiel J. Th. Rutgers; Lawrence J. Solin; Fattaneh Tavassoli; Daniela A. Terribile; Michael Untch.*
19. **Fornier M**. Etoposides in Breast Cancer: Review of Clinical Experience. **Ann Oncol**, 2007 18: v16-v21.

Monica N. Fornier, M.D.

20. **Fornier M.** Ixabepilone, first in a new class of antineoplastics, the natural epothilones and their analogs. **Clinical Breast Cancer** 2007, Oct;7 (10):757-63.
21. Farooki A, **Fornier M**, Girotra M. Anabolic therapies for osteoporosis. **N Engl J Med** 2007, 357(23):2410-1
22. Atzori F, **Fornier M.** Epothilones in breast cancer: current status and future directions. **Expert Rev Anticancer Ther**, 2008 (8):1299-311.
23. Morris PG, **Fornier M.** Microtubule active agents **Clin Cancer Res** 2008, 15;14(22):7167-72.
24. Morris PG, **Fornier MN.** Novel anti-tubulin cytotoxic agents for breast cancer. **Expert Rev Anticancer Ther** 2009, 9(2):175-85.
25. Gralow JR, Biermann JS, Farooki A, **Fornier MN**, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. **J Natl Compr Canc Netw** 2009, 7 Suppl 3:S1-S32.
26. Morris PG, **Fornier MN.** Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer. **Clin Adv Hematol Oncol.** 2009, 7(2):115-22.
27. Schiavon G, Maki RG, **Fornier M.** GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. **Curr Cancer Ther Rev** 2009, 100-104(5).
28. Morris PG, **Fornier MN.** Optimizing the use of anthracyclines in older patients with breast cancer. **Crit Rev Oncol Hematol** 2011, 77(2):131-41.
29. Murphy CG, **Fornier MN.** HER2 positive breast cancer: beyond trastuzumab. **Oncology (Williston Park).** 2010, 30; 24(5):410-5.
30. Comen E, **Fornier MN.** Algorithms for Treatment of Patients with Pretreated Metastatic Breast Cancer with Prior Exposure to Taxanes and Anthracyclines. **Clin Breast Cancer** 2010, 10 Suppl 2:S7-19.
31. **Fornier M.** Denosumab: the second chapter in treating bone metastases or a new book? **J Clin Oncol** 2010, 28(35):5127-31.
32. **Fornier MN.** Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. **Clin Breast Cancer** 2010, 1;10(5):352-8.
33. **Fornier MN.** Approved agents for metastatic breast cancer. **Semin Oncol** 2011;38 Suppl 2:S3-10.
34. **Fornier M**, Fumoleau P. The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment. **Breast J** 2012, 18(1):41-51.
35. Twelves CJ, **Fornier MN.** Managing patients with heavily pre-treated metastatic breast cancer: balancing efficacy and safety. **Comm Oncol** 2012, 9: 5s.
36. Gralow JR, Biermann JS, Farooki A, **Fornier MN**, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. **J Natl Compr Canc Netw.** 2013;11 Suppl 3:S1-S50.

Monica N. Fornier, M.D.

37. Cadoo KA, **Fornier MN**, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. **Q J Nucl Med Mol Imaging**. 2013;57(4):312-21.
38. Farooki A, **Fornier M**, Boland P. Atypical femur fractures associated with use of bisphosphonates and denosumab. **Ann Oncol**. 2015 Apr;26(4):819-20.
39. Ramnarain B, Page D, **Fornier M**. Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials. **Breast Cancer Manag**. 2015 4 (3), 135-144.
40. Farooki A, **Fornier M**. Denosumab and fracture risk in women with breast cancer. **Lancet** 2015 Nov 21;386(10008):2056-7.
41. **Fornier MN**. Less Intense Dosing Schedule for a Bone-Modifying Agent. **JAMA Oncol** 2017; Jul 1;3(7):893-894.
42. Ferraro E, **Fornier MN**. Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy. **Ann Transl Med**. 2020 Dec;8(24):1694. doi: 10.21037/atm-20-5406.